Stock quote - Summary

Summit Therapeutics
SUMM: 182.50 0.00 ( 0.00 %) delayed: 16:57PM
Bid price 180.00 High price 0.00
Ask price 185.00 Low price 0.00
Open price 188.00 Spread 2.70%
Prev close 182.50 Volume 0

Summit Therapeutics - Share price charts

Intraday
You need to install or upgrade your Flash Player
Historic - 1 year
You need to install or upgrade your Flash Player

Advanced Summit Therapeutics charts >

Summit Therapeutics - Share price information
Name Summit Therapeutics Epic SUMM
Activities Summit Therapeutics plc (formerly Summit Corporation plc, formerly VASTox plc) is an international biopharmaceutical company focussed on the discovery and development of novel medicines to treat the fatal muscle wasting disease Duchenne Muscular Dystrophy and infections caused by the bacteria C. difficile. Summit's goal is to become a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies. ISIN GB00BN40HZ01
Latest Share Price (p) 182.50 Net Gearing (%) 34.64
Market Capitalisation (pm) 130.50 Gross Gearing (%) 109.29
Shares in issue (m) 70.54 Debt Ratio 113.09
P/E Ratio -4.21 Debt-to-Equity Ratio 0.74
Total dividends per share (p) 0.00 Assets / Equity Ratio -10.76
Dividend Yield (%) 0.00 Price to book value -29.66
Dividend Cover 0.00 ROCE (%) -96.31
Earning per share (p) -44.00 EPS Growth (%) -7.32
52-week high / low (p) 265.00 / 141.50 DPS Growth (%) n/a
Summit Therapeutics - Broker views
Date Broker Recommendation Price Old target price New target price Notes
19 Jan N+1 Singer Corporate - - Reiterates
15 Dec N+1 Singer Corporate - - Reiterates
21 Oct N+1 Singer Corporate - - Reiterates
28 Sep N+1 Singer Corporate - - Reiterates
27 Sep N+1 Singer Corporate - - Reiterates

More Summit Therapeutics broker views >

Summit Therapeutics - Director deals
Date Director Type Volume / Price Trade value
30 Jul 2014 Glyn Edwards Buy 30,000 @ 104.50p £31,350.00
26 Jul 2013 Jim Mellon Placing 20,000,000 @ 5.00p £1,000,000.00
26 Jul 2013 Barry Price Placing 500,000 @ 5.00p £25,000.00
26 Jul 2013 Dr Frank Armstrong Placing 50,000 @ 5.00p £2,500.00
26 Jul 2013 Glyn Edwards Placing 600,000 @ 5.00p £30,000.00

More Summit Therapeutics director deals >

Risk warning: Remember the price of shares can go down as well as up, and you are not guaranteed to get back the amount that you originally invested.
Click here to read the full warning.

Capita Asset Services is a trading name of Capita IRG Trustees Limited which is authorised and regulated by the Financial Conduct Authority and which is also authorised to conduct cross-border business within the EEA under the provisions of the EU Markets in Financial Instruments Directive. Registered office: The Registry, 34 Beckenham Road, Beckenham, Kent BR3 4TU. Registered in England and Wales No. 2729260.

www.capitaassetservices.com